JT-001
drugOn this page
Also known as Jt001
Summary
Jt-001 (CHEMBL5219660) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including type 2 diabetes mellitus and severe acute respiratory syndrome.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 2 conditions
- Clinical trials: 6
- Chemistry: 402.5 Da · C19H22N4O4S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5219660 |
| Name | JT-001 |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 135240787 |
| Molecular formula | C19H22N4O4S |
| Molecular weight | 402.5 |
| InChIKey | KWSGPJCQWZMUQM-UHFFFAOYSA-N |
SMILES: C1CC2=CC3=C(CCC3)C(=C2C1)NC(=O)NS(=O)(=O)C4=C5N(CCCO5)N=C4
IUPAC name: 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea
Also known as: Jt-001, Jt001, JT-001
Patent coverage: 2 distinct patent families (9 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: NACHT, LRR and PYD domains-containing protein 3.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| NLRP3 | 7.2 | IC50 | 63 | nM | CHEMBL_ACT_24969630 |
| NLRP3 | 5.92 | IC50 | 1210 | nM | CHEMBL_ACT_24969638 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| type 2 diabetes mellitus | 3 | MONDO:0005148 | MONDO:0005148 |
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
Clinical trials
Total trials: 6.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 4 |
| PHASE2/PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05101135 | PHASE3 | UNKNOWN | To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin |
| NCT05242042 | PHASE2/PHASE3 | TERMINATED | JT001 (VV116) for the Early Treatment of COVID-19 |
| NCT05279235 | PHASE3 | TERMINATED | Efficacy and Safety of JT001 (VV116) Compared With Favipiravir |
| NCT05341609 | PHASE3 | COMPLETED | Efficacy and Safety of JT001 (VV116) Compared With Paxlovid |
| NCT05582629 | PHASE3 | COMPLETED | JT001 (VV116) for the Treatment of COVID-19 |
| NCT06142201 | Not specified | ACTIVE_NOT_RECRUITING | A Real-World Study of JT001 for COVID-19 |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).